ARTICLE | Strategy
Lantus limbo
What Sanofi's Lantus rebates mean for new insulin candidates launching in 2015
November 17, 2014 8:00 AM UTC
The abrupt slowing of Lantus sales in the U.S. could augur reimbursement pressure for new insulin candidates entering the market from Sanofi and its competitors.
A halving of U.S. sales growth for Lantus insulin glargine in the third quarter compared with the prior year's growth rate is one of the reasons Sanofi's board said it removed CEO Christopher Viehbacher and put Chairman Serge Weinberg in his place while the pharma seeks a permanent replacement (see Cover Story)...